AstraZeneca’s osimertinib plus savolitinib beats chemotherapy in MET-driven EGFR-mutated lung cancer

Phase III SAFFRON data show osimertinib plus savolitinib cut progression or death risk by 45% and death risk by 32% versus chemotherapy in MET-driven epidermal growth factor receptor-mutated non-small cell lung cancer after osimertinib progression; a New Drug Application has been submitted to the FDA based on the SAFFRON results …

A flat vector illustration showing a wide teal gate lifting open as two groups of plain boxes of slightly different sizes queue to pass through, with tiny faceless silhouettes nearby.

CLINICAL CATALYST · ONCOLOGY · NOVEMBER 1, 2026 · GLOBAL

Phase III data for a biomarker-defined subgroup of lung cancer were presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on Oct. 25, when AstraZeneca and HUTCHMED, which jointly develop savolitinib, reported results from the SAFFRON trial. The combination of osimertinib (Tagrisso) plus savolitinib (Orpathys) reduced the risk of disease progression or death by 45% and the risk of death by 32% compared with doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors carried high levels of MET (mesenchymal-epithelial transition factor) overexpression or amplification and who had progressed on prior osimertinib, according to the AstraZeneca press release. The results were simultaneously published in The New England Journal of Medicine.

The headline figures: a progression-free survival (PFS) hazard ratio (HR) of 0.55 (95% confidence interval [CI] 0.42–0.72; p<0.001), with median PFS of 7.6 months for the combination versus 5.4 months for chemotherapy, per blinded independent central review (BICR). At 12 months, an estimated 36% of patients treated with the combination remained progression-free compared with 10% in the chemotherapy arm. Overall survival (OS) HR was 0.68 (95% CI 0.50–0.91; p=0.010), with median OS of 17.8 months for the combination versus 12.9 months — a difference of 4.9 months. An estimated 70% of patients in the combination arm were alive at one year, against 53% in the chemotherapy arm. These are the primary and key secondary endpoints of a global Phase III trial, not a subgroup analysis. The Full Analysis Set included 338 patients (171 in the combination arm, 167 in the chemotherapy arm) at 230 centers in 29 countries across North America, Europe, South America and Asia, per the press release.

OS HR 0.68

Osimertinib plus savolitinib reduced the risk of death by 32% versus chemotherapy (OS HR 0.68; 95% CI 0.50–0.91) in MET-driven EGFRm NSCLC after osimertinib, per the AstraZeneca SAFFRON press release.

Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, and principal investigator of SAFFRON, said the results ‘have the potential to establish a new global standard of care for the third of patients with EGFR-mutated non-small cell lung cancer experiencing high levels of MET-driven resistance after osimertinib,’ adding that ‘there are currently no well-tolerated, oral, biomarker-directed treatment options to address this frequent driver of disease progression,’ per the AstraZeneca press release.

An all-oral option versus intravenous chemotherapy

The clinical significance of the combination’s delivery format is not incidental. Platinum-based doublet chemotherapy — the comparator in SAFFRON — is given intravenously, in cycles that require infusion infrastructure. Osimertinib plus savolitinib is entirely oral. Susan Galbraith, Executive Vice President of Oncology Haematology Research and Development at AstraZeneca, described the combination as having ‘the potential to become the first biomarker-directed, all-oral treatment option in this setting,’ per the AstraZeneca press release, while noting that it ‘directly addresses MET-driven resistance while maintaining EGFR suppression.’

The safety profile was consistent with the known profiles of each medicine individually, per the press release. Grade 3 or higher treatment-emergent adverse events from all causes occurred in 64% of patients treated with the combination and 63% in the chemotherapy arm — a near-identical rate. Median total duration of treatment exposure was more than twice as long for the combination (8.5 months) compared with the chemotherapy arm (3.5 months), per the press release.

The PFS benefit was consistent across all prespecified subgroups, including patients whose tumors had MET overexpression and those with MET amplification, per the press release. In the MET-overexpressed analysis set (127 patients in the combination arm, 118 in the chemotherapy arm), median PFS was 8.5 months versus 5.6 months (HR 0.51; 95% CI 0.37–0.71; p<0.001). In the MET-amplified analysis set (129 versus 116 patients), median PFS was 7.64 months versus 4.2 months (HR 0.487; 95% CI 0.35–0.66); the press release noted that no formal statistical testing was carried out for this analysis set.

The regulatory and commercial pipeline

Based on the SAFFRON Phase III trial results, a New Drug Application (NDA) has been submitted to the FDA for osimertinib plus savolitinib for the treatment of patients with locally advanced or metastatic NSCLC whose tumors have MET overexpression or amplification and who had disease progression on or after an EGFR-tyrosine kinase inhibitor (TKI) therapy, per the press release. The combination is already approved in China for patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy, based on the earlier SACHI Phase III trial; savolitinib has been marketed in China since 2021, per Fierce Pharma. It also has a temporary authorization in Switzerland based on the SAVANNAH Phase II trial, per the press release.

The commercial context for AstraZeneca is material. The company has set an ambition to deliver $80 billion in total revenue by 2030, according to a 2024 AstraZeneca announcement.

A structural tension in the SAFFRON data deserves attention. The trial enrolled patients with high levels of MET overexpression or amplification — a biomarker-defined population that requires prospective testing to identify. Professor Lu’s statement that this affects ‘the third of patients’ with EGFRm NSCLC who experience MET-driven resistance after osimertinib implies that routine MET testing at progression will become a clinical prerequisite for the combination to reach its eligible population. Payers and health systems that have not embedded MET testing into post-progression workflows face a diagnostic infrastructure question that precedes any formulary decision.

The press release said results from the SANOVO Phase III trial — evaluating osimertinib plus savolitinib in treatment-naive patients in China with EGFRm locally advanced or metastatic NSCLC and MET overexpression — would be presented at the ESMO Congress the following day (abstract LBA69). SANOVO’s results were not detailed in the SAFFRON announcement, but the trial’s existence suggests that the companies are pursuing a label that could extend the combination into earlier lines of therapy, well upstream of the post-osimertinib resistance setting that SAFFRON addresses.

What to Watch

  1. FDA review timeline and any advisory committee convened for the osimertinib plus savolitinib NDA, given the biomarker-defined population and the SACHI data that preceded SAFFRON
  2. SANOVO Phase III results in treatment-naive EGFRm NSCLC with MET overexpression — a positive readout could substantially expand the addressable population and reshape the competitive sequence
  3. Payer and health technology assessment body responses to the MET-testing requirement, particularly whether coverage decisions will mandate companion diagnostic use as a condition of reimbursement
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper signal from SAFFRON is about the architecture of osimertinib’s commercial franchise rather than a single approval. By demonstrating that savolitinib can address what Professor Lu called a frequent driver of disease progression after osimertinib — MET-driven resistance — AstraZeneca appears positioned to extend osimertinib’s role from a first-line standard into a backbone that anchors sequential combination strategies.

SAFFRON Trial · Osimertinib + Savolitinib vs Chemotherapy (Full Analysis Set, BICR)

Combination Arm Chemotherapy Arm
Median progression-free survival (months) 7.6 5.4
PFS hazard ratio 0.55 (95% CI 0.42–0.72; p<0.001)
PFS rate at 12 months 36% 10%
Median overall survival (months) 17.8 12.9
OS hazard ratio 0.68 (95% CI 0.50–0.91; p=0.010)
OS rate at 12 months 70% 53%
Grade 3+ treatment-emergent adverse events 64% 63%
Median treatment exposure (months) 8.5 3.5

Why this is relevant

Patients

The SAFFRON trial, sponsored by AstraZeneca, showed that osimertinib plus savolitinib extended median overall survival (OS) by 4.9 months and median progression-free survival (PFS) by 2.2 months versus platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and MET-driven resistance after osimertinib, offering an all-oral alternative to intravenous chemotherapy in this setting, per the AstraZeneca press release.

Industry

An NDA for the combination has been submitted to the FDA based on SAFFRON results, per the AstraZeneca press release. The SANOVO Phase III trial in treatment-naive patients in China with MET overexpression, scheduled for presentation at ESMO the following day, suggests the companies are pursuing a broader label that could extend the combination upstream of the post-osimertinib resistance setting.

Payers

Coverage decisions for osimertinib plus savolitinib, if approved, could require companion MET diagnostic testing as a condition of reimbursement, creating a diagnostic infrastructure requirement that precedes formulary inclusion and may affect the speed at which eligible patients access the combination in practice.

Regulators

The FDA NDA covers locally advanced or metastatic NSCLC with MET overexpression or amplification after EGFR-TKI progression; the combination is already approved in China based on the SACHI Phase III trial, per the AstraZeneca press release. The FDA review will determine whether the global SAFFRON data satisfy US approval standards for this biomarker-defined population.

Sources: AstraZeneca: SAFFRON Phase III press release, Oct. 25, 2026 · ClinicalTrials.gov: SAFFRON (NCT05261399) · Fierce Pharma: AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure · AstraZeneca: ambition to deliver $80 billion Total Revenue by 2030 (May 21, 2024)

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related